ArticleThe Journal of clinical endocrinology and metabolism2023
Platelet-Lymphocyte and Neutrophil-Lymphocyte Ratios Are Prognostic Markers for Pheochromocytomas and Paragangliomas.
Article in The Journal of clinical endocrinology and metabolism, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Multi-omics insights into metastatic pheochromocytomas and paragangliomas: Mechanisms, signatures, and prediction models.Hormones (Athens, Greece) · 2026Review
- FT3 Levels and Systemic Inflammation: Evidence From a Population-Based NHANES Analysis.Mediators of inflammation · 2026Article
- The evolving roles of pathologists in paragangliomas and pheochromocytomas.Virchows Archiv : an international journal of pathology · 2026Review
- Development and validation of an explainable machine learning model for predicting postoperative venous thromboembolism in esophageal cancer.International journal of surgery (London, England) · 2026Article
- Clinical parameters-based machine learning models for predicting intraoperative hemodynamic instability in hypertensive pheochromocytomas and paragangliomas patients.World journal of urology · 2025Article
- Inflammation-based Scores in Patients With Pheochromocytoma.The Journal of clinical endocrinology and metabolism · 2025Article
- Voxel-based morphometry reveals immune-metabolic dysregulation driving adaptive cortical gray matter remodeling in patients with esophageal cancer.Frontiers in oncology · 2025Article
- RNA sequencing reveals transcriptomic changes in PC-12 cells following plasminogen activator, tissue type overexpression.Translational cancer research · 2024Article
- Preoperative systemic inflammatory response index as a prognostic marker for distal cholangiocarcinoma after pancreatoduodenectomy.World journal of gastrointestinal surgery · 2024Article
- Performance of nutritional and inflammatory markers in patients with pancreatic cancer.World journal of clinical oncology · 2024Article
- The Immune Landscape of Pheochromocytoma and Paraganglioma: Current Advances and Perspectives.Endocrine reviews · 2024Review
- Efficacies of anlotinib monotherapy versus gemcitabine-based chemotherapy for patients with advanced soft tissue sarcoma after the failure of anthracycline-based chemotherapy.Journal of cancer research and clinical oncology · 2024Article
- Immune Landscape of Pheochromocytoma and Paraganglioma: A Potentially Novel Avenue for Prognostic Reclassification?The Journal of clinical endocrinology and metabolism · 2023Article
Corrections and comments
- Commented on by
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextPreoperative inflammatory markers, such as the neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and lymphocyte-monocyte ratio (LMR), have recently been proposed as prognostic markers in different tumors. However, their predictive values in patients with pheochromocytomas and paragangliomas (PPGLs) are uncertain.
objectiveThis study aimed to investigate the prognostic significance of inflammatory biomarkers in PPGL patients.
methodsData from 1247 consecutive PPGL patients between 2002 and 2020 were evaluated. The preoperative inflammatory markers were evaluated. The prognostic roles were identified by X-tile software, Kaplan-Meier curves, and Cox regression models.
resultsA total of 728 patients were included in the analysis, with a median follow-up of 63 months (IQR, 31-111 months); 31 individuals died, 28 patients developed metastases, and 12 patients developed recurrence. Our study showed that deaths were observed significantly more frequently in patients with high NLR(≥3.5) and high PLR (≥217.4) than those with low NLR (<3.5) (P = .003) and low PLR (<217.4) (P = .005). Elevated NLR (≥3.5) and elevated PLR (≥217.4) was significantly associated with decreased overall survival (OS) (P = .005), and elevated PLR (≥238.3) was significantly associated with decreased metastasis-free survival (MFS) (P = .021). Cox models illustrated that NLR and PLR were independent prognostic factors for OS, and PLR was an independent prognostic factor for MFS.
conclusionBoth elevated NLR and PLR are associated with poor prognosis in PPGLs. They are convenient predictive markers that could be used in daily clinical practice.
Indexed as
Identifiers
36917004What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.